Robert F. Kennedy Jr. is facing pushback from the American Psychiatric Association over his controversial claims about selective serotonin reuptake inhibitors, the most commonly prescribed class of antidepressants.
Kennedy has repeatedly suggested SSRIs cause violence and other serious side effects, claims that psychiatrists say misrepresent the scientific evidence. The APA statement emphasizes that Kennedy's position amounts to an oversimplification of complex neuroscience and clinical practice.
The psychiatric group notes that while SSRIs carry warnings about potential risks in certain populations, particularly adolescents, the drugs remain a cornerstone of depression and anxiety treatment for millions of Americans. The organization points out that untreated mental illness itself carries substantial risks.
Kennedy's vaccine skepticism has extended into psychiatry. During his campaign and media appearances, he has promoted the idea that SSRIs are overused and dangerous, positioning himself as a truth-teller challenging pharmaceutical industry interests. These claims have gained traction among some segments of his audience.
The APA's response reflects broader concern among mental health professionals that Kennedy's influence as a potential government official could affect public confidence in psychiatric medications and treatment. Fewer patients seeking help due to medication fears could worsen mental health outcomes across the country.
The organization does agree with Kennedy on one point: the mental health system needs improvement. The APA acknowledges too many Americans lack access to comprehensive mental health care and welcomes investments in evidence-based treatment options. The disagreement centers on whether reducing SSRI use represents sound policy or reckless medical advice.
Kennedy's views on psychiatric drugs reflect his broader skepticism toward pharmaceutical solutions and his preference for what he frames as natural approaches. Mental health advocates worry this could discourage people from seeking treatment they need.
THE TAKEAWAY: Kennedy's blanket skepticism of SSRIs conflicts with psychiatric science, but his criticism highlights real access and care